CORCEPT THERAPEUTICS I

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

24 Jun 2024 15:15:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

06 Jun 2024 08:45:18 By NetDania Notify

NetDania - New 12 months High: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

05 Jun 2024 12:50:40 By NetDania Notify

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

01 May 2024 15:05:00 By Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 4 CATALYST Trial

29 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

24 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

22 Apr 2024 08:59:41 By NetDania Notify

Corcept Announces Positive Results From Open-Label Portion of Pivotal Phase 3 GRACE Trial in Patients With Cushing’s Syndrome

22 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 2 DAZALS Trial in Patients With Amyotrophic Lateral Sclerosis (ALS)

15 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer

08 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 Feb 2024 15:07:00 By Nasdaq GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 Feb 2024 15:02:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Corcept Appoints Roberto Vieira as President, Oncology

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

08 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Court Finds Corcept Therapeutics’ Patents Not Infringed

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

01 Nov 2023 15:05:00 By Nasdaq GlobeNewswire